Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F25%3A43921435" target="_blank" >RIV/00023752:_____/25:43921435 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/25:43927874

Výsledek na webu

<a href="https://www.cambridge.org/core/journals/european-psychiatry/article/use-of-psychedelic-treatments-in-psychiatric-clinical-practice-an-epa-policy-paper/340B7D729CF69904BB989B24FA0D60F7" target="_blank" >https://www.cambridge.org/core/journals/european-psychiatry/article/use-of-psychedelic-treatments-in-psychiatric-clinical-practice-an-epa-policy-paper/340B7D729CF69904BB989B24FA0D60F7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1192/j.eurpsy.2024.1806" target="_blank" >10.1192/j.eurpsy.2024.1806</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper

Popis výsledku v původním jazyce

Background Recent years show an exponential increased interest (&quot;renaissance&quot;) in the use of psychedelics for the treatment of mental disorders and broader. Some of these treatments, such as psilocybin for depression, are in the process of formal regulation by regulatory bodies in the US (FDA) and Europe (EMA), and as such on the brink of real-world implementation. In the slipstream of these developments increasing commercial initiatives are taking shape. The European Psychiatric Association (EPA) acknowledges both the therapeutic potential of psychedelic substances and the challenges for both research and clinical implementation. Steps need to be taken toward a well-balanced policy based upon sound scientific evidence and research, aiming at safe, ethical responsible integration of psychedelic therapy available for all patients who can potentially benefit.Methods In this EPA policy paper, we highlight the potential benefits, and also the challenges of psychedelic treatments, which can be relevant for the future real-world implementation of these treatments.Results In addition to an overview of the current evidence and hypotheses of working mechanisms of psychedelic treatment, this policy paper specifically highlights the importance of the psychosocial components of the treatment as well as the ethical and professional aspects playing a role in real-world implementation.Conclusions Four recommendations are formulated for further research and clinical implementation.

Název v anglickém jazyce

Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper

Popis výsledku anglicky

Background Recent years show an exponential increased interest (&quot;renaissance&quot;) in the use of psychedelics for the treatment of mental disorders and broader. Some of these treatments, such as psilocybin for depression, are in the process of formal regulation by regulatory bodies in the US (FDA) and Europe (EMA), and as such on the brink of real-world implementation. In the slipstream of these developments increasing commercial initiatives are taking shape. The European Psychiatric Association (EPA) acknowledges both the therapeutic potential of psychedelic substances and the challenges for both research and clinical implementation. Steps need to be taken toward a well-balanced policy based upon sound scientific evidence and research, aiming at safe, ethical responsible integration of psychedelic therapy available for all patients who can potentially benefit.Methods In this EPA policy paper, we highlight the potential benefits, and also the challenges of psychedelic treatments, which can be relevant for the future real-world implementation of these treatments.Results In addition to an overview of the current evidence and hypotheses of working mechanisms of psychedelic treatment, this policy paper specifically highlights the importance of the psychosocial components of the treatment as well as the ethical and professional aspects playing a role in real-world implementation.Conclusions Four recommendations are formulated for further research and clinical implementation.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30215 - Psychiatry

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Psychiatry

ISSN

0924-9338

e-ISSN

1778-3585

Svazek periodika

68

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

FR - Francouzská republika

Počet stran výsledku

7

Strana od-do

"e3"

Kód UT WoS článku

001393055300001

EID výsledku v databázi Scopus

2-s2.0-85214906699